Cell therapy produces encouraging first results in eye trialUK-based biotech ReNeuron has announced encouraging results from an early stage trial of its cell therapy for the Share XCell therapy produces encouraging first results in eye trialhttps://pharmaphorum.com/news/reneuron-cell-therapy-produces-encouraging-results-in-early-eye-trial/
UK biotech gets grant for further trial of osteoarthritis drugUK biotech AKL Research and Development (AKLRD) has received a grant from a UK government-backed innovation body to Share XUK biotech gets grant for further trial of osteoarthritis drughttps://pharmaphorum.com/news/uk-biotech-gets-grant-for-further-trial-of-osteoarthritis-drug/
UCB joins with UK charity to research new epilepsy drugsBelgium’s UCB has joined forces with the UK’s Epilepsy Society in a collaboration aimed at finding treatments for Share XUCB joins with UK charity to research new epilepsy drugshttps://pharmaphorum.com/news/ucb-joins-with-uk-charity-to-research-new-epilepsy-drugs/
Pharma companies clear the R&D decks in Q4The fourth-quarter results season has already seen a host of unwanted projects cleared from pharma companies’ pipelines as Share XPharma companies clear the R&D decks in Q4https://pharmaphorum.com/news/pharma-companies-clear-the-rd-decks-in-q4/
Gene therapy biotech shares sink on inconclusive trial resultsShares in two US gene therapy biotechs have fallen after two cutting-edge treatments failed to produce convincing results Share XGene therapy biotech shares sink on inconclusive trial resultshttps://pharmaphorum.com/news/gene-therapy-biotech-shares-sink-on-inconclusive-trial-results/
R&D roundup: the ups and downs of CRISPR and Alzheimer’sWhile the controversy surrounding Vertex Pharma’s cystic fibrosis drug in the UK grows more intense, the US firm Share XR&D roundup: the ups and downs of CRISPR and Alzheimer’shttps://pharmaphorum.com/r-d/views-analysis-r-d/rd-roundup-the-ups-and-downs-of-crispr-and-alzheimers/
GSK bolts-on immuno-oncology candidate with €3.7bn Merck dealGlaxoSmithKline is making another big play in cancer, signing a wide-ranging deal with Merck KGaA for M7824, an Share XGSK bolts-on immuno-oncology candidate with €3.7bn Merck dealhttps://pharmaphorum.com/news/gsk-bolts-on-immuno-oncology-candidate-with-e3-7bn-merck-deal/
AZ’s lung drug gets fast development in EU and USRegulators in the US and Europe have fast-tracked development of AstraZeneca’s MEDI8897, an antibody drug aimed at preventing Share XAZ’s lung drug gets fast development in EU and UShttps://pharmaphorum.com/news/us-and-eu-accelerate-medi8897/
Lilly scores with two Olumiant trials in atopic dermatitisEli Lilly has two positive trials of its JAK inhibitor Olumiant in skin disorder atopic dermatitis (AD), which Share XLilly scores with two Olumiant trials in atopic dermatitishttps://pharmaphorum.com/news/lilly-scores-with-two-olumiant-trials-in-atopic-dermatitis/
